SE0400208D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
SE0400208D0
SE0400208D0 SE0400208A SE0400208A SE0400208D0 SE 0400208 D0 SE0400208 D0 SE 0400208D0 SE 0400208 A SE0400208 A SE 0400208A SE 0400208 A SE0400208 A SE 0400208A SE 0400208 D0 SE0400208 D0 SE 0400208D0
Authority
SE
Sweden
Prior art keywords
chemical compounds
compounds
chemokine
modulators
activity
Prior art date
Application number
SE0400208A
Other languages
English (en)
Swedish (sv)
Inventor
Lilian Alcaraz
Mark Furber
Chris Luckhurst
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0400208A priority Critical patent/SE0400208D0/xx
Publication of SE0400208D0 publication Critical patent/SE0400208D0/xx
Priority to CA002553089A priority patent/CA2553089A1/en
Priority to NZ548781A priority patent/NZ548781A/en
Priority to RU2006130686/04A priority patent/RU2348616C2/ru
Priority to US10/587,633 priority patent/US7956070B2/en
Priority to CNA2005800103948A priority patent/CN1938274A/zh
Priority to JP2006551005A priority patent/JP4814109B2/ja
Priority to KR1020067015578A priority patent/KR20060128992A/ko
Priority to UY28731A priority patent/UY28731A1/es
Priority to EP05704776A priority patent/EP1713772A1/en
Priority to PCT/SE2005/000110 priority patent/WO2005073192A1/en
Priority to BRPI0507366-9A priority patent/BRPI0507366A/pt
Priority to AU2005207817A priority patent/AU2005207817B2/en
Priority to TW094103106A priority patent/TW200529843A/zh
Priority to ARP050100391A priority patent/AR049770A1/es
Priority to IL176992A priority patent/IL176992A0/en
Priority to ZA200606199A priority patent/ZA200606199B/xx
Priority to CO06073840A priority patent/CO5700747A2/es
Priority to NO20063921A priority patent/NO20063921L/no
Priority to JP2008226791A priority patent/JP2009019055A/ja
Priority to AU2008229856A priority patent/AU2008229856A1/en
Priority to RU2008140910/04A priority patent/RU2008140910A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
SE0400208A 2004-02-02 2004-02-02 Chemical compounds SE0400208D0 (sv)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SE0400208A SE0400208D0 (sv) 2004-02-02 2004-02-02 Chemical compounds
NZ548781A NZ548781A (en) 2004-02-02 2005-01-31 Piperidine derivatives as chemokine modulators (CCR)
PCT/SE2005/000110 WO2005073192A1 (en) 2004-02-02 2005-01-31 Novel piperidines as chemokine modulators (ccr)
AU2005207817A AU2005207817B2 (en) 2004-02-02 2005-01-31 Novel piperidines as chemokine modulators (CCR)
RU2006130686/04A RU2348616C2 (ru) 2004-02-02 2005-01-31 Новые пиперидины в качестве модуляторов хемокинов (ccr)
US10/587,633 US7956070B2 (en) 2004-02-02 2005-01-31 Piperidines as chemokine modulators (CCR)
CNA2005800103948A CN1938274A (zh) 2004-02-02 2005-01-31 用作趋化因子调节剂(ccr)的新哌啶化合物
JP2006551005A JP4814109B2 (ja) 2004-02-02 2005-01-31 ケモカイン・モジュレーター（ｃｃｒ）としての新規ピペリジン類
KR1020067015578A KR20060128992A (ko) 2004-02-02 2005-01-31 케모카인 조절제 (ｃｃｒ)로서의 신규 피페리딘
UY28731A UY28731A1 (es) 2004-02-02 2005-01-31 Compuestos quimicos
EP05704776A EP1713772A1 (en) 2004-02-02 2005-01-31 Novel piperidines as chemokine modulators (ccr)
CA002553089A CA2553089A1 (en) 2004-02-02 2005-01-31 Novel piperidines as chemokine modulators (ccr)
BRPI0507366-9A BRPI0507366A (pt) 2004-02-02 2005-01-31 novas piperidinas como moduladores de quimiocima (ccr)
TW094103106A TW200529843A (en) 2004-02-02 2005-02-01 Chemical compounds
ARP050100391A AR049770A1 (es) 2004-02-02 2005-02-02 Derivados de piperidina como moduladores de la actividad de quimioquinas
IL176992A IL176992A0 (en) 2004-02-02 2006-07-20 Novel piperidines as chemokine modulators (ccr)
ZA200606199A ZA200606199B (en) 2004-02-02 2006-07-26 Novel piperidines as chemokine modulators (CCR)
CO06073840A CO5700747A2 (es) 2004-02-02 2006-07-27 Piperidinas novedosas como moduladores de quimoquina (ccr)
NO20063921A NO20063921L (no) 2004-02-02 2006-09-01 Nye piperidiner som kjemokinmodulatorer (CCR)
JP2008226791A JP2009019055A (ja) 2004-02-02 2008-09-04 ケモカイン・モジュレーター（ｃｃｒ）としての新規ピペリジン類
AU2008229856A AU2008229856A1 (en) 2004-02-02 2008-10-09 Novel piperidines as chemokine modulators (CCR)
RU2008140910/04A RU2008140910A (ru) 2004-02-02 2008-10-16 Новые пиперидины в качестве модуляторов хемокинов (ccr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0400208A SE0400208D0 (sv) 2004-02-02 2004-02-02 Chemical compounds

Publications (1)

Publication Number Publication Date
SE0400208D0 true SE0400208D0 (sv) 2004-02-02

Family

ID=31713276

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0400208A SE0400208D0 (sv) 2004-02-02 2004-02-02 Chemical compounds

Country Status (19)

Country Link
US (1) US7956070B2 (no)
EP (1) EP1713772A1 (no)
JP (2) JP4814109B2 (no)
KR (1) KR20060128992A (no)
CN (1) CN1938274A (no)
AR (1) AR049770A1 (no)
AU (2) AU2005207817B2 (no)
BR (1) BRPI0507366A (no)
CA (1) CA2553089A1 (no)
CO (1) CO5700747A2 (no)
IL (1) IL176992A0 (no)
NO (1) NO20063921L (no)
NZ (1) NZ548781A (no)
RU (2) RU2348616C2 (no)
SE (1) SE0400208D0 (no)
TW (1) TW200529843A (no)
UY (1) UY28731A1 (no)
WO (1) WO2005073192A1 (no)
ZA (1) ZA200606199B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
SE0400208D0 (sv) * 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
TW200812582A (en) * 2006-04-06 2008-03-16 Astrazeneca Ab Medicaments
US7897621B2 (en) 2008-03-31 2011-03-01 Hoffmann-La Roche Inc. 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents
TWI433838B (zh) * 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
TW201418242A (zh) 2012-10-26 2014-05-16 Du Pont 作為除草劑之經取代的三唑
EP3164394B1 (en) 2014-07-03 2020-04-01 Board of Regents, The University of Texas System Gls1 inhibitors for treating diseases
WO2016004417A1 (en) * 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease
ES2794868T3 (es) 2015-06-30 2020-11-19 Univ Texas Inhibidores de GLS1 para el tratamiento de enfermedades
EP3394039A4 (en) 2015-12-22 2019-06-12 Board of Regents, The University of Texas System SALT FORMS AND POLYMORPHS OF (R) -1- (4- (6- (2- (4- (3,3-DIFLUOROCYCLOBUTOXY) -6-METHYLPYRIDIN-2-YL) ACETAMIDO) PYRIDAZIN-3-YL) -2 -FLUOROBUTYL) -N-METHYL-1H-1,2,3-triazole-4-carboxamide
WO2019079632A1 (en) 2017-10-18 2019-04-25 Board Of Regents, The University Of Texas System GLUTAMINASE INHIBITOR THERAPY
WO2020025574A1 (en) 2018-08-03 2020-02-06 Bayer Aktiengesellschaft Process for the preparation of 6-(haloalkyl)-2-halo-5-acylpyridines and intermediates for this process
CN113121417A (zh) * 2019-12-30 2021-07-16 苏州盛迪亚生物医药有限公司 一种新型哌啶衍生物及其药物用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118768A (en) * 1995-07-12 2000-10-31 Akzo Nobel Nv Diphenylmethane piperidine derivatives pharmaceutical compositions containing them and a method for their preparation
JPH0977742A (ja) 1995-09-12 1997-03-25 Kyorin Pharmaceut Co Ltd 新規なベンズアミド誘導体
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
DE69629846T2 (de) 1996-10-28 2004-07-08 Schering Corp. Substituierte arylalkylamine als neurokinin-antagonisten
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
EP1003514A4 (en) 1997-07-25 2000-10-11 Merck & Co Inc CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6166037A (en) * 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6140349A (en) * 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
CN1163484C (zh) 1998-11-17 2004-08-25 霍夫曼-拉罗奇有限公司 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
AU1774600A (en) 1998-11-20 2000-06-13 F. Hoffmann-La Roche Ag Piperidine ccr-3 receptor antagonists
DE69926806D1 (de) 1998-12-18 2005-09-22 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
AU2057200A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035454A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6605623B1 (en) * 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2482100A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3126600A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6331541B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3386400A (en) * 1999-03-02 2000-09-21 Merck & Co., Inc. 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
SK11822001A3 (sk) 1999-03-26 2002-09-10 Astrazeneca Ab Modulátory chemokínovej aktivity, spôsoby ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie v terapii
US6358979B1 (en) * 1999-06-11 2002-03-19 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
SE9902551D0 (sv) 1999-07-02 1999-07-02 Astra Pharma Prod Novel compounds
SE9902765D0 (sv) 1999-07-21 1999-07-21 Astra Pharma Prod Novel compounds
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
AU2001271357A1 (en) 2000-06-21 2002-01-02 Dupont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1294690A2 (en) 2000-06-21 2003-03-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CN1440402A (zh) * 2000-06-30 2003-09-03 布里斯托尔-迈尔斯斯奎布公司 作为趋化因子受体活性调节剂的n－脲基杂环烷基－哌啶
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
US6855553B1 (en) 2000-10-02 2005-02-15 3M Innovative Properties Company Sample processing apparatus, methods and systems
WO2002030899A1 (en) * 2000-10-09 2002-04-18 Novartis Ag N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr3 receptor antagonists
CA2436699A1 (en) 2000-12-21 2002-06-27 Warner-Lambert Company Llc Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
GB0117899D0 (en) * 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
EP1490043A4 (en) 2002-03-26 2007-05-30 Merck & Co Inc SPIROCYCLIC AMIDS AS CANNABINOID RECEPTOR MODULATORS
SE0400208D0 (sv) * 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
TW200812582A (en) 2006-04-06 2008-03-16 Astrazeneca Ab Medicaments

Also Published As

Publication number Publication date
RU2006130686A (ru) 2008-03-10
NZ548781A (en) 2008-11-28
AR049770A1 (es) 2006-09-06
CA2553089A1 (en) 2005-08-11
CN1938274A (zh) 2007-03-28
ZA200606199B (en) 2008-04-30
CO5700747A2 (es) 2006-11-30
NO20063921L (no) 2006-11-02
US7956070B2 (en) 2011-06-07
IL176992A0 (en) 2006-12-10
UY28731A1 (es) 2005-09-30
JP2007519717A (ja) 2007-07-19
JP2009019055A (ja) 2009-01-29
AU2005207817B2 (en) 2008-07-24
AU2008229856A1 (en) 2008-11-06
RU2008140910A (ru) 2010-04-27
EP1713772A1 (en) 2006-10-25
TW200529843A (en) 2005-09-16
AU2005207817A1 (en) 2005-08-11
RU2348616C2 (ru) 2009-03-10
US20070054924A1 (en) 2007-03-08
BRPI0507366A (pt) 2007-07-03
WO2005073192A1 (en) 2005-08-11
KR20060128992A (ko) 2006-12-14
JP4814109B2 (ja) 2011-11-16

Similar Documents

Publication Publication Date Title
NO20063921L (no) Nye piperidiner som kjemokinmodulatorer (CCR)
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
DK1888541T3 (da) Benzo(d)isoxazol-3-yl-amin-forbindelser og anvendelse af disse som vanilloidreceptorligander
ATE433447T1 (de) Pyrimiidinverbindungen
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
TW200720271A (en) DNA-PK inhibitors
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
EA200602241A1 (ru) Замещённые индазолы, композиции, содержащие указанные индазолы, способ их получения и применение
SE0401762D0 (sv) Novel compounds
MA28707B1 (fr) Utilisation de 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines substituees lors du traitement de nausees et de vomissements
NO20073033L (no) Cytotoksiske midler innbefattende nye taksaner
GEP20104941B (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
EA200701114A1 (ru) Азоловые производные с антимускариновой активностью
EA201100424A1 (ru) Новые ингибиторы
DE602006009789D1 (de) Acetylenderivate
UA98608C2 (en) Benzofused five-membered heterocycles and use thereof
TW200728273A (en) Catalytic process for preparing (meth)acrylates of N-hydroxyalkylated lactams
SE0400850D0 (sv) Novel Compounds
GB0508318D0 (en) Organic compounds
TW200716132A (en) Novel chemical compounds
NO20081292L (no) Pentasykliske kinaseinhibitorer
SE0300850D0 (sv) Chemical compounds
MX2008001428A (es) Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
SE0403085D0 (sv) Novel componds
SE0403086D0 (sv) Compounds